| Literature DB >> 29287707 |
Andrew T Reid1, Punnam Chander Veerati2, Reinoud Gosens3, Nathan W Bartlett2, Peter A Wark4, Chris L Grainge4, Stephen M Stick5, Anthony Kicic6, Fatemeh Moheimani2, Philip M Hansbro2, Darryl A Knight7.
Abstract
Dysregulated induction of goblet cell differentiation results in excessive production and retention of mucus and is a common feature of several chronic airways diseases. To date, therapeutic strategies to reduce mucus accumulation have focused primarily on altering the properties of the mucus itself, or have aimed to limit the production of mucus-stimulating cytokines. Here we review the current knowledge of key molecular pathways that are dysregulated during persistent goblet cell differentiation and highlights both pre-existing and novel therapeutic strategies to combat this pathology. CrownKeywords: Asthma; COPD; Cystic fibrosis; Epithelium; Goblet cell; Mechanical stress; Monoclonal antibody therapy; Mucus; Signaling pathways; Therapeutic; micro-RNA
Mesh：
Year: 2017 PMID： 29287707 DOI： 10.1016/j.pharmthera.2017.12.009
Source DB: PubMed Journal: Pharmacol Ther ISSN： 0163-7258 Impact factor: 12.310